Literature DB >> 26892877

Brain inflammation, neurodegeneration and seizure development following picornavirus infection markedly differ among virus and mouse strains and substrains.

Sonja Bröer1, Christopher Käufer2, Verena Haist3, Lin Li4, Ingo Gerhauser3, Muneeb Anjum2, Marion Bankstahl2, Wolfgang Baumgärtner4, Wolfgang Löscher5.   

Abstract

Infections, particularly those caused by viruses, are among the main causes of acquired epilepsy, but the mechanisms causing epileptogenesis are only poorly understood. As a consequence, no treatment exists for preventing epilepsy in patients at risk. Animal models are useful to study epileptogenesis after virus-induced encephalitis and how to interfere with this process, but most viruses that cause encephalitis in rodents are associated with high mortality, so that the processes leading to epilepsy cannot be investigated. Recently, intracerebral infection with Theiler's murine encephalomyelitis virus (TMEV) in C57BL/6 (B6) mice was reported to induce early seizures and epilepsy and it was proposed that the TMEV mouse model represents the first virus infection-driven animal model of epilepsy. In the present study, we characterized this model in two B6 substrains and seizure-resistant SJL/J mice by using three TMEV (sub)strains (BeAn-1, BeAn-2, DA). The idea behind this approach was to study what is and what is not necessary for development of acute and late seizures after brain infection in mice. Receiver operating characteristic (ROC) curve analysis was used to determine which virus-induced brain alterations are associated with seizure development. In B6 mice infected with different TMEV virus (sub)strains, the severity of hippocampal neurodegeneration, amount of MAC3-positive microglia/macrophages, and expression of the interferon-inducible antiviral effector ISG15 were almost perfect at discriminating seizing from non-seizing B6 mice, whereas T-lymphocyte brain infiltration was not found to be a crucial factor. However, intense microglia/macrophage activation and some hippocampal damage were also observed in SJL/J mice. Overall, the TMEV model provides a unique platform to study virus and host factors in ictogenesis and epileptogenesis.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Encephalitis; Epileptogenesis; Hippocampal damage; ISG15; Infection; Interferon; Macrophages; Microglia; Seizures

Mesh:

Year:  2016        PMID: 26892877     DOI: 10.1016/j.expneurol.2016.02.011

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  25 in total

1.  Acute treatment with minocycline, but not valproic acid, improves long-term behavioral outcomes in the Theiler's virus model of temporal lobe epilepsy.

Authors:  Melissa L Barker-Haliski; Taylor D Heck; E Jill Dahle; Fabiola Vanegas; Timothy H Pruess; Karen S Wilcox; H Steve White
Journal:  Epilepsia       Date:  2016-10-14       Impact factor: 5.864

2.  Morphine-potentiated cognitive deficits correlate to suppressed hippocampal iNOS RNA expression and an absent type 1 interferon response in LP-BM5 murine AIDS.

Authors:  Virginia D McLane; Saurabh Kumar; Reno Leeming; Sanjay Rau; Colin L Willis; Ling Cao
Journal:  J Neuroimmunol       Date:  2018-03-06       Impact factor: 3.478

Review 3.  The relevance of inter- and intrastrain differences in mice and rats and their implications for models of seizures and epilepsy.

Authors:  Wolfgang Löscher; Russell J Ferland; Thomas N Ferraro
Journal:  Epilepsy Behav       Date:  2017-06-23       Impact factor: 2.937

Review 4.  Theiler's murine encephalomyelitis virus infection of SJL/J and C57BL/6J mice: Models for multiple sclerosis and epilepsy.

Authors:  Ana Beatriz DePaula-Silva; Tyler J Hanak; Jane E Libbey; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2017-02-12       Impact factor: 3.478

Review 5.  Molecular Mechanisms in the Genesis of Seizures and Epilepsy Associated With Viral Infection.

Authors:  Wolfgang Löscher; Charles L Howe
Journal:  Front Mol Neurosci       Date:  2022-05-09       Impact factor: 6.261

Review 6.  The current approach of the Epilepsy Therapy Screening Program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy.

Authors:  Karen S Wilcox; Peter J West; Cameron S Metcalf
Journal:  Neuropharmacology       Date:  2019-11-30       Impact factor: 5.273

7.  Neuroinflammation in epileptogenesis: Insights and translational perspectives from new models of epilepsy.

Authors:  Melissa L Barker-Haliski; Wolfgang Löscher; H Steve White; Aristea S Galanopoulou
Journal:  Epilepsia       Date:  2017-07       Impact factor: 6.740

8.  Neuroprotection mediated by inhibition of calpain during acute viral encephalitis.

Authors:  Charles L Howe; Reghann G LaFrance-Corey; Kanish Mirchia; Brian M Sauer; Renee M McGovern; Joel M Reid; Eric J Buenz
Journal:  Sci Rep       Date:  2016-06-27       Impact factor: 4.379

Review 9.  The National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP).

Authors:  John H Kehne; Brian D Klein; Shamsi Raeissi; Shalini Sharma
Journal:  Neurochem Res       Date:  2017-05-02       Impact factor: 4.414

Review 10.  Commonalities in epileptogenic processes from different acute brain insults: Do they translate?

Authors:  Pavel Klein; Raymond Dingledine; Eleonora Aronica; Christophe Bernard; Ingmar Blümcke; Detlev Boison; Martin J Brodie; Amy R Brooks-Kayal; Jerome Engel; Patrick A Forcelli; Lawrence J Hirsch; Rafal M Kaminski; Henrik Klitgaard; Katja Kobow; Daniel H Lowenstein; Phillip L Pearl; Asla Pitkänen; Noora Puhakka; Michael A Rogawski; Dieter Schmidt; Matti Sillanpää; Robert S Sloviter; Christian Steinhäuser; Annamaria Vezzani; Matthew C Walker; Wolfgang Löscher
Journal:  Epilepsia       Date:  2017-12-15       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.